Combination of | |
---|---|
Tropicamide | Anticholinergic |
Phenylephrine | Alpha-1 adrenergic receptor agonist |
Clinical data | |
Trade names | Mydcombi |
Routes of administration | Topical, ophthalmic |
ATC code | |
Legal status | |
Legal status |
Tropicamide/phenylephrine, sold under the brand name Mydcombi is a fixed dose combination of tropicamide and phenylephrine used to dilate the eyes (mydriasis).[1] It contains, tropicamide, an anticholinergic, and phenylephrine, as the hydrochloride, an alpha-1 adrenergic receptor agonist.[1] It is sprayed into the eyes.[1]
It was approved for medical use in the United States in May 2023.[2][3]
Tropicamide/phenylephrine is used for the short-term dilation of the pupils.[1]
α1 |
| ||||
---|---|---|---|---|---|
α2 |
| ||||
β |
| ||||
Phenethylamines |
|
---|---|
Amphetamines |
|
Phentermines |
|
Cathinones |
|
Phenylisobutylamines | |
Phenylalkylpyrrolidines | |
Catecholamines (and close relatives) |
|
Miscellaneous |
|